Lytix Biopharma AS (FRA:6BG)
Germany flag Germany · Delayed Price · Currency is EUR
0.8040
+0.0120 (1.52%)
Last updated: Feb 23, 2026, 8:11 AM CET

Lytix Biopharma AS Balance Sheet

Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
10.6130.7927.3794.55197.28
Short-Term Investments
61.76-23.1850.61-
Cash & Short-Term Investments
72.36130.7950.55145.16197.28
Cash Growth
-44.68%158.75%-65.18%-26.42%593.43%
Accounts Receivable
-0.46---
Other Receivables
7.0812.112.1265.13
Receivables
7.0812.5612.1265.13
Prepaid Expenses
-0.550.660.740.55
Other Current Assets
--0--
Total Current Assets
79.44143.963.33151.89202.96
Property, Plant & Equipment
2.092.630.551.382.14
Other Long-Term Assets
0--0-
Total Assets
81.52146.5463.87153.27205.1
Accounts Payable
6.385.023.5771.48
Accrued Expenses
-24.442.382.113.77
Current Portion of Leases
0.980.760.450.870.83
Current Income Taxes Payable
-1.191.360.952.03
Other Current Liabilities
11.25.364.746.836.06
Total Current Liabilities
18.5536.7612.5117.7614.17
Long-Term Leases
1.221.880.040.481.34
Other Long-Term Liabilities
--0---
Total Liabilities
19.7738.6412.5618.2415.51
Common Stock
6.836.824.014.013.87
Additional Paid-In Capital
54.92101.0847.31131.03185.72
Comprehensive Income & Other
0----0
Shareholders' Equity
61.75107.8951.32135.03189.59
Total Liabilities & Equity
81.52146.5463.87153.27205.1
Total Debt
2.22.640.491.342.17
Net Cash (Debt)
70.16128.1550.06143.81195.11
Net Cash Growth
-45.25%156.01%-65.19%-26.29%585.80%
Net Cash Per Share
1.032.371.253.635.88
Filing Date Shares Outstanding
68.2668.2640.0740.0740.07
Total Common Shares Outstanding
68.2668.1640.0740.0738.74
Working Capital
60.88107.1450.81134.13188.8
Book Value Per Share
0.901.581.283.374.89
Tangible Book Value
61.75107.8951.32135.03189.59
Tangible Book Value Per Share
0.901.581.283.374.89
Machinery
-0.20.20.15-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.